Thymosin Alpha-1 common uses, half-life, side effects and more

Thymosin alpha-1 is a natural 28-amino-acid peptide made by the thymus gland. It helps regulate the immune system. Its nonproprietary drug name is thymalfasin. It is an approved prescription medicine in more than 30 countries. The main approved use is chronic hepatitis B. Some countries also use it for hepatitis C, cancer care, and vaccine response. The FDA has never approved it in the United States. American wellness and longevity clinics prescribe compounded thymosin alpha-1 off label for immune support, frequent infections, and lingering post-viral symptoms. It is also sold gray-market as a research chemical. The FDA has flagged compounded injectable versions for possible impurities and immune reactions.

• Approved treatment for chronic hepatitis B outside the United States
• Add-on to interferon for hepatitis C in older trials
• Immune support in serious illness such as sepsis and acute pancreatitis in hospital trials
• Adjunct to cancer treatment and vaccination in some countries
• Off-label immune support for frequent infections and lingering post-viral symptoms
• Gray-market immune and longevity self-experimentation

Twice weekly or a lower daily dose

The subcutaneous dose most people use is 1.6 mg twice weekly. This figure comes from the hepatitis B drug label and the trials behind it. A hepatitis B course runs 6 to 12 months. Some telehealth clinics instead prescribe a lower daily microdose of about 500 mcg on five days a week. Hospital trials in acute illness such as sepsis used more frequent dosing of up to every 12 hours. Higher doses of 3.2 to 6.4 mg come from cancer studies and are not used for general immune support.

The plasma half-life is about 2 hours in humans after subcutaneous injection. Blood levels fall back to baseline within a day. The immune effect lasts much longer than the plasma level. Twice-weekly dosing works despite the short half-life.

• Injection-site discomfort, redness, and itching are the most common effects
• Flu-like symptoms such as mild fever, muscle aches, and malaise occur less often
• Rash, transient muscle atrophy, and joint aches with hand swelling are rare events on the drug label
• Allergic reactions such as itching, swelling, or trouble breathing are possible but rare

Thymosin alpha-1 works through both the innate and adaptive arms of the immune system. It has no known dedicated receptor of its own. Instead it acts mainly through Toll-like receptors on dendritic cells. Animal antiviral models show it activating a TLR9 pathway that drives interferon production. Downstream it helps dendritic cells mature, improves antigen presentation, and pushes T-cells toward a Th1 antiviral profile. It also supports natural killer cell activity and shifts the mix of signaling cytokines. The overall effect is described as context-dependent. It can restore immune responses when they are weak and calm them when they are overactive. The precise molecular steps are still debated.

Thymosin alpha-1 has been studied in humans for decades. Most of that study is in serious illness rather than the wellness uses it is now sold for. The best older data are small hepatitis B and C trials from the 1990s that used 1.6 mg twice weekly and showed modest antiviral effects that never led to FDA approval. The sepsis, liver-failure, and pancreatitis research comes mostly from one Chinese critical-care group and many small single-center trials of low quality. The apparent benefits shrink or disappear in the higher-quality and multicenter subgroups. The largest and most rigorous sepsis trial gave over 1,100 patients the drug or placebo and found no survival benefit. A COVID-19 analysis also found no overall benefit in hospitalized adults. No controlled trials support the immune-optimization, Lyme, or long-COVID uses sold by wellness clinics.

• No FDA-approved product containing thymosin alpha-1 exists in the United States
• Deliberate immunosuppression such as after an organ transplant is a labeled contraindication because boosting immunity can trigger rejection
• Combining it with other immune-activating drugs including cancer checkpoint immunotherapy has caused severe immune reactions in a case report
• Pregnancy, breastfeeding, and use under age 18 have no established safety
• Athletes should not confuse it with the banned thymosin beta-4 or TB-500 and should confirm its status with their anti-doping organization before use
• Gray-market injectable and nasal products may carry inaccurate identity, impurities, or contamination